While most 340B covered entities do not share their contract pharmacy claims data with drug makers to restore access to 340B pricing, many would do so if the process was better and got 340B pricing turned back on reliably, a new survey by pharmaceutical distributor McKesson found.
Seventy-two percent of 340B covered entities said in the survey that they do not give their contract pharmacy drug claims data to a drug industry contractor to get 340B pricing back for certain manufacturers’ drugs if the entities want the products to be shipped to multiple contract pharmacies. Of these, however, only 37% were a hard no. Another 34% said either they definitely will report or are considering reporting data but that resources are a barrier.
While most 340B covered entities do not share their contract pharmacy claims data with drug makers to restore access to 340B pricing, many would do so if the process was better and got 340B pricing turned back on reliably, a new survey by pharmaceutical distributor McKesson found.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
